Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Drug Cardiovascular Risk Should Be Extended to Strattera, Cmte. Says

Executive Summary

Warnings about cardiovascular risk associated with pediatric use of attention deficit/hyperactivity disorder treatments should be extended to Lilly's Strattera, FDA's Pediatric Advisory Committee recommended

You may also be interested in...



ADHD Class Warnings Could Be Strengthened Pending FDA Research

Despite FDA's recent approval of class warning language for attention deficit/hyperactivity disorder treatments, the agency will continue research in an effort to better characterize the extent of stimulant side effects in ADHD patients, Division of Psychiatry Products Director Thomas Laughren indicated

ADHD Class Warnings Could Be Strengthened Pending FDA Research

Despite FDA's recent approval of class warning language for attention deficit/hyperactivity disorder treatments, the agency will continue research in an effort to better characterize the extent of stimulant side effects in ADHD patients, Division of Psychiatry Products Director Thomas Laughren indicated

Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling

Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval

Related Content

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel